DS Biopharma Announces Notification of Patent Allowance for U.S. Application 13/478,982 Protecting DS107F, a Next Generation Acne Therapy
Select Preclinical Data to be Presented at the ICAAC Meeting
Dublin, Ireland, September 10, 2012 – DS Biopharma, a privately held biopharmaceutical company, announced today that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Patent Application Serial Number 13/478,982, titled “Pharmaceutical Compositions Comprising DGLA, 15-OHEPA, and/or 15-HETrE and Methods of use Thereof.” The application has claims that protect the composition and the methods of using DS107F. The granted patent will provide DS107F exclusivity though at least 2032.
Jonathan Rowe PhD, Head of Intellectual Property and Portfolio Strategy stated, “One of DS Biopharma’ key strategic themes is to acquire and develop intellectual property in order to bring to patients safe, effective and well tolerated world-class products. We expect this notice of allowance to be only a first in our promising, robust IP portfolio developed by our highly skilled team at DS Biopharma.”
On September 12th at the ICAAC meeting in San Francisco, DS Biopharma will be presenting a poster entitled “Dihomo γ-Linolenic Acid (DGLA) Enhances the Antimicrobial Efficacy of Benzoyl Peroxide”. The session will take place from 9:15-11:15 a.m. PST at poster F-2009. This presentation contains select preclinical data that was described in the ‘982 patent application.
DS107 is a topical formulation of a semi-synthetic derivative of DGLA and benzoyl peroxide. DS107F is currently being developed as an advanced therapy for treating acne.
About DS Biopharma
DS Biopharma, a privately held biopharmaceutical company, was established to discover and develop scientifically innovative healthcare solutions that improve the quality of life of people with diseases for which current therapies are unsatisfactory. DS Biopharma is led by recognized experts in developing fatty acids, including their bioactive derivatives, for the treatment of human disease.
DS Biopharma: email@example.com, +35312933590
Updated from Dignity Sciences to DS Biopharma as of 11th May 2015